目的 研究血脂康膠囊聯(lián)合辛伐他汀的調(diào)脂作用及對(duì)24 h尿白蛋白排泄量、血漿內(nèi)皮素-1水平的影響。方法 選擇2012年1月—2016年12月在渭南市第一醫(yī)院進(jìn)行診治的高脂血癥患者96例，隨機(jī)分為觀察組與對(duì)照組，每組各45例。對(duì)照組口服辛伐他汀治療，觀察組聯(lián)合口服血脂康膠囊治療，兩組均治療3個(gè)月。比較兩組的臨床治療效果，以及兩組治療前后的24 h尿白蛋白排泄量、血漿內(nèi)皮素-1水平。結(jié)果 觀察組的有效率為93.75%（45/48），明顯高于對(duì)照組的77.08%（37/48），差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。兩組治療后的血脂水平均明顯改善，同組治療前后比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05），且觀察組明顯優(yōu)于對(duì)照組，差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。兩組治療后的24 h尿白蛋白排泄量與治療前相比無(wú)顯著差異，兩組治療后的血漿內(nèi)皮素-1水平明顯降低，同組治療前后比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05），且觀察組明顯優(yōu)于對(duì)照組，差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。結(jié)論 血脂康膠囊聯(lián)合辛伐他汀對(duì)高脂血癥患者具有顯著的調(diào)脂作用，并可以有效降低血漿內(nèi)皮素-1水平，提示長(zhǎng)期進(jìn)行調(diào)脂治療可以有效保護(hù)血管內(nèi)皮細(xì)胞功能。

Objective To investigate the clinical effect of Xuezhikang Capsule combined with simvastatin on lipid regulating and excretion of urine albumin and endothelin -1 level in 24 hours. Methods Selected 96 cases of patients with hyperlipidemia who were treated in our hospital from January 2012 to December 2016, divided into two groups randomly. The control group was treated with simvastatin, and the observation group was treated with Xuezhikang capsule. The clinical effects of the two groups were compared, and the urinary albumin excretion rate and endothelin-1 level of 24 hours before and after treatment in the two groups were measured. Results After treatment, the effective rate of the observation group was 93.75% (45/48), significantly higher than that of the control group 77.08% (37/48) (P<0.05); the blood lipid levels of the two groups were significantly improved (P<0.05), and the observation group was significantly better than that of the control group (P<0.05); there was no significant difference in urinary albumin excretion between the two groups after 24 hours treatment; the level of endothelin-1 in the two groups was significantly lower than that in the control group (P<0.05), and the observation group was significantly better than the control group (P<0.05). Conclusion Xuezhikang Capsule combined with simvastatin has good lipid-lowering effect on patients with hyperlipidemia, and can effectively reduce the plasmaendothelin-1 level, suggesting that long-term lipid-lowering therapy can effectively protect the function of vascular endothelial cells.